Moderna

Moderna experienced a volatile trading session today as investors reassessed expectations following the Phase 3 melanoma trial announcement for intismeran, the cancer vaccine co-developed with Merck. Shares plunged to $180.50 intraday—a decline exceeding 9%—as market participants reacted negatively to data that fell short of the exceptionally elevated pre-release expectations, but afternoon sentiment shifted as investors reconsidered the data's therapeutic value, ultimately driving a rebound to $207.97, closing up 4.6%. Analyst William Blair downgraded the stock to 'Market Perform,' citing the 574% year-to-date surge as justification for trimming exposure after such an extended rally. Notably, at current levels Moderna trades just 18% below its 52-week peak of $254.48 recorded only six days prior; yet Q2 financial results underscore growing pressures—the company posted a net loss of $782M while revenue growth decelerated to just 2.1% year-over-year, highlighting a stark valuation disconnect given the stock's $83B market capitalization and 574% year-to-date appreciation.

Moderna took a hit as Phase 3 clinical data from its intismeran melanoma vaccine missed expectations, sending the stock down sharply in premarket trading—dropping about 9% from the prior close of $200.10 to a session low of $176.70—before staging a partial recovery during regular trading to close at $198.85. Citi maintained a bearish stance on the company following the disappointing vaccine trial results. Despite the recent setback, Moderna has surged roughly 544% year-to-date from $30.86 to the current $198.85, remaining above its 60-day moving average of $154.75; however, the stock has retreated some 22% from its 52-week high of $254.48 set just recently on October 21st. On the earnings front, the company reported net losses of $782 million in Q2 and $1.343 billion in Q1, underscoring its current unprofitable state.

Moderna plunged approximately 17.6% today, dropping from yesterday's close of $245.81 to $202.63, with an intraday low of $181.26, primarily driven by the company's cancer vaccine data leaking via social media and sparking market panic. The underlying trial data is actually positive—in a Phase 3 study with Merck for melanoma treatment, the vaccine reduces death or recurrence risk by over 40%—yet the premature disclosure and information confusion triggered investor risk-off positioning. Pre-market trading remained relatively stable at $239.26, but rapid selling accelerated during regular session before bouncing back to $195.93 in after-hours trading. Analysts at Mizuho noted the selloff reflects market's high expectations bar rather than poor data quality. MRNA has surged over 556% year-to-date, just reaching a 52-week high of $254.48 on October 21, though the company faces ongoing losses (Q2 net loss of $782 million).

Moderna surged 7% on October 20 and climbed another 4.46% on October 21, primarily driven by Bank of America's significant upgrade raising its price target to $220 and strong investor anticipation for imminent cancer vaccine clinical trial data. The company's transformational pivot from COVID vaccines to oncology, highlighted by FDA filing plans for melanoma vaccine candidate and multiple oncology programs, has resonated powerfully with market sentiment. Technically, Moderna set a 52-week high of $254.48 on the 21st with an intraday peak of $254.12; though post-market pullback to $245.18 signaled profit-taking, the full-day gain of +1.54% held ground well above both 20-day and 60-day moving averages. Year-to-date appreciation reached an extraordinary +696.53%, with market capitalization surging to $98.1 billion. Despite this momentum, the company remains loss-making with Q2 net losses of $782 million, underscoring embedded assumptions about cancer vaccine commercial success and corresponding valuation risk at current levels.

Moderna closed 6.7% higher at $242.08 today, reaching a 52-week peak of $243.98 after an intraday dip to $217.15, primarily fueled by FDA filing plans for its melanoma vaccine and clinical data release for mRNA-3927 targeting propionic acidemia. Bank of America raised its price target to $220, underlining confidence in the company's oncology pipeline. The stock has gained 684% year-to-date and now trades just 0.78% below its 52-week high, substantially above the 20-day ($206.85) and 60-day ($144.35) moving averages. However, profitability remains challenging: Q2 showed net losses of $782 million against just $145 million in revenue, with PE in negative territory and PB at 14.29, suggesting current valuations already embed considerable market optimism around new products.